NEO, US64049M2098

NeoGenomics stock gets BTIG Buy upgrade at USD 28 target

Published on 10/08/2026 at 02:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BTIG upgraded NeoGenomics stock to Buy with a USD 28.00 target on October 6, 2026. Preliminary Q3 revenue reached USD 209 million.

NEO, US64049M2098, Illustration mit AI erstellt.

NeoGenomics stock (ISIN US64049M2098) was last at USD 16.50 on Nasdaq on October 6, 2026, down 13.72 percent from the previous session. The same day, BTIG upgraded the shares from Neutral to Buy and set a USD 28.00 price target, according to Markets Insider on October 6, 2026.

BTIG sees a valuation gap

BTIG based its call on valuation, citing a multiple of 3 times NeoGenomics' 2027 consensus revenue against 11 times for specialty laboratory peers, as Markets Insider reported. The USD 28.00 target stands USD 11.50 above the October 6 price, putting the target 69.7 percent above that price.

The valuation argument competes with a sharp near-term reset in the stock. The October 6 move followed NeoGenomics' leadership announcement and preliminary third-quarter outlook, while the company continues to operate in oncology diagnostics and laboratory testing.

Revenue growth meets leadership change

NeoGenomics said on October 5, 2026, that Warren Stone will become chief executive officer on January 4, 2027, while Tony Zook will become executive chairman. The announcement also projected preliminary Q3 2026 revenue of USD 209 million and next-generation sequencing revenue growth of 28 percent, according to the NeoGenomics release.

The release said full-year revenue guidance would be increased at the midpoint after the third-quarter performance, while reiterating adjusted EBITDA guidance issued on July 28, 2026. That combination gives investors two separate checkpoints: faster diagnostic growth and execution through a planned management transition.

Consensus target stays near the stock

MarketBeat listed a Moderate Buy consensus from 10 analysts on October 6, 2026, with six Buy ratings, three Holds and one Sell. Its average 12-month target was USD 17.67, which places the target 7.1 percent above the USD 16.50 price.

The consensus figure is materially below BTIG's USD 28.00 target, making the spread between individual analyst views a central valuation issue. NeoGenomics' second-quarter 2026 revenue was USD 201.66 million, up 11.2 percent year over year, while adjusted EPS was USD 0.05 versus a USD 0.03 consensus estimate, according to MarketBeat.

NeoGenomics stock faces the next test

NeoGenomics is scheduled to report third-quarter 2026 results before the market opens on October 27, 2026, with an 8:30 a.m. ET conference call, according to MarketBeat. That report will show whether the USD 209 million preliminary revenue projection translates into a broader guidance increase.